Last reviewed · How we verify
EXS21546 Granule in Capsule
At a glance
| Generic name | EXS21546 Granule in Capsule |
|---|---|
| Sponsor | Exscientia AI Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours (PHASE1, PHASE2)
- 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXS21546 Granule in Capsule CI brief — competitive landscape report
- EXS21546 Granule in Capsule updates RSS · CI watch RSS
- Exscientia AI Limited portfolio CI